JW-2286 / JW Pharma - LARVOL DELTA

To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: JW Pharmaceutical | Not yet recruiting ➔ Recruiting

Enrollment open

To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: JW Pharmaceutical

New P1 trial

JW2286, a STAT3-targeted anticancer drug from JW Pharmaceuticals, receives IND approval for phase 1 clinical trials [Google translation] (Medical Observer) - "JW Pharmaceutical announced on the 19th that it has received approval from the Ministry of Food and Drug Safety for a phase 1 clinical trial (IND) for JW2286, a STAT3 inhibitor being developed as a treatment for solid tumors....This clinical trial will evaluate safety, tolerability, and pharmacokinetic characteristics in approximately 70 healthy Korean and Caucasian adults at Seoul National University Hospital."

New P1 trial • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

JW proposes solid tumor drug candidate at AACR (Korea Biomedical Review) - "JW Pharmaceutical said Tuesday that it has confirmed its anticancer candidate, JW-2286, inhibits STAT3 (signal transducer and activator of transcription 3) and potently impairs the growth and survival of triple-negative breast cancer (TNBC). At the American Association for Cancer Research's annual meeting, the company said its candidate substance JW-2286 blocks STAT3 leading to mitochondrial dysfunction and AMPK activation, which suppresses the tumor growth."

Preclinical • Breast Cancer • Oncology • Triple Negative Breast Cancer